Medications.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Parkinson’s Disease Medications By David Houghton, MD, MPH, Howard Hurtig, MD, and Sharon Metz, RN, MPH, with guest authors Monique Giroux, MD, Giselle Petzinger, MD, Beth Fisher, PT, PhD, Lauren Hawthorne, BS, and Michael Jakowec, PhD 301277_NPF-Medications.indd 1 10/30/17 1:24 PM Parkinson’s Disease: Medications 301277_NPF-Medications.indd 2 10/30/17 1:24 PM Parkinson’s Disease: Medications Table of Contents Chapter 1 Introduction to Parkinson’s Disease..........................................................5 Chapter 2 Medications for Motor Symptoms ............................................................8 Chapter 3 Medications for Non-Motor Symptoms ................................................21 Chapter 4 Exercise Is Medicine ................................................................................... 46 Chapter 5 Integrative Medicine ................................................................................... 49 Chapter 6 Research and Future Developments ......................................................63 Summary of Tables Table 1 Symptoms in Parkinson’s Disease ............................................................6 Table 2 Medications for Motor Symptoms in PD ..................................................9 Table 3 Medications for Depression and Anxiety in PD ...................................25 Table 4 Medications for Dementia and Hallucinations in PD .........................32 Table 5 Medications for Gastrointestinal (GI) Symptoms and Drooling in PD ............................................................................................... 40 Appendix A Glossary ..........................................................................................................67 Appendix B Medical Alert Card .......................................................................................72 Appendix C Formula for Liquid Sinemet .......................................................................73 Appendix D Epworth Sleepiness Scale .........................................................................74 Appendix E Selected Readings........................................................................................75 About the Authors ............................................................................................................................76 Index ............................................................................................................................78 301277_NPF-Medications.indd 3 10/30/17 1:24 PM Parkinson’s Disease: Medications Introduction This book concentrates on the medications used in Parkinson’s disease (PD). Ideally, the treatment of PD would be symptomatic (control or reduction of symptoms), neuroprotective (halting or slowing of disease progression) and neuroregenerative (reversal of disease process). At present, proven therapies only help to relieve symptoms. More than a dozen different medications are now being used routinely to combat the motor symptoms of PD. Many others target the non-motor complications of PD. Considerable research remains dedicated to uncovering neuroprotective or neuroregenerative strategies, but to date, no such definitive therapies have been discovered. Throughout this manual, medications currently available for symptomatic treatment and future developments in the treatment of PD are discussed. 4 301277_NPF-Medications.indd 4 10/30/17 1:24 PM Parkinson’s Disease: Medications Chapter 1 Introduction to Parkinson’s Disease Classic Symptoms The primary symptoms of Parkinson’s disease (PD) were first described by James Parkinson in 1817 in his Essay on the Shaking Palsy. These include: • Tremor (usually most noticeable when the limb is at rest) • Bradykinesia (slowness of movement) • Rigidity (stiffness of movement) • Postural instability (imbalance when standing or walking) A PD diagnosis is based on evidence of at least two out of three specific signs and symptoms: tremor, slowed mobility (bradykinesia) and/or stiffness (rigidity). The occurrence of symptoms on only one side of the body is typical of the disease in its earliest stage. The diagnosis of Parkinson’s disease remains clinical; that is, there are no conventional or readily available laboratory tests or brain images that can “prove” PD, though dopamine transporter scanning may help with diagnostic puzzles (see discussion in Pathology section). Other characteristic features of PD include: • Micrographia (small handwriting) • Hypophonic dysarthria (soft, less understandable speech) • Stooped posture • Shuffling steps • Diminished facial expression • Infrequent eye blinking Early falling or postural instability, commonly seen later in classic PD, may suggest other parkinsonian syndromes such as: • Progressive supranuclear palsy (PSP) • Corticobasal degeneration (CBD) • Multiple system atrophy (MSA) • Dementia with Lewy bodies (DLB) As the above symptoms predominantly involve movement, they are called motor symptoms. Parkinson’s disease is not only a disorder of motor symptoms. It is now well known that non-motor symptoms also can be prominent and even disabling in PD. Non- motor symptoms include changes in mood, memory, blood pressure, bowel and bladder function, sleep, fatigue, weight and sensation (Table 1). Some symptoms have features of both (i.e., mixed motor and non-motor symptoms). 5 301277_NPF-Medications.indd 5 10/30/17 1:24 PM Parkinson’s Disease: Medications Table 1. Symptoms in Parkinson’s Disease MOTOR SYMPTOMS • Bradykinesia (slowness of movement) • Rigidity (stiffness of movement) • Tremor (involuntary shaking of the hands, feet, arms, legs, jaw or tongue; usually more prominent at rest) • Postural instability (tendency to fall, usually when pivoting) NON-MOTOR SYMPTOMS • Mood changes (depression, anxiety, irritability) • Cognitive changes (memory problems, personality changes, psychosis/hallucinations) • Orthostatic hypotension (lightheadedness and low blood pressure when standing) • Constipation and early satiety (a feeling of fullness after eating small amounts) • Hyperhidrosis (excessive sweating) • Seborrhea (oily skin) • Urinary urgency and incontinence • Sexual dysfunction • Loss of sense of smell • Sleep disorders • Insomnia, excessive daytime sleepiness (EDS), rapid eye movement behavioral disorder (RBD) or active dreaming, dream enactment, involuntary movements and vocalizations during sleep, restless leg syndrome (RLS)/periodic limb movement disorder (PLMD) • Fatigue • Sensory problems (pain, tightness, tingling, burning) MIXED MOTOR AND NON-MOTOR SYMPTOMS • Drooling due to slowed swallowing (sialorrhea) • Speech and swallowing problems 6 301277_NPF-Medications.indd 6 10/30/17 1:24 PM Parkinson’s Disease: Medications Much clinical research is being conducted to try to recognize early features of Parkinson’s disease. Motor symptoms typically begin on one side of the body, often as a rest tremor or a reduced ability to use the hand, arm or leg on the affected side. Prior to the appearance of the motor features of PD, individuals may also recognize that they have experienced constipation, vivid dreams, depression and/or diminished sense of smell for months or even years. These “pre-motor” symptoms may provide the opportunity for earliest recognition of the PD complex, with more clinical trials and earlier treatment strategies on the horizon. PATHOLOGY Parkinson’s disease is a result of the loss of specific types of brain cells (neurons) that produce a chemical called dopamine. The motor symptoms come from the slow and progressive degeneration and death of these neurons in an area of the brain called the substantia nigra, which is in the brain stem. One reason these brain cells begin to die may be due to genetic abnormalities. The earliest symptoms of PD usually don’t appear for several years after the onset of neurodegeneration because there is plenty of dopamine left in reserve to compensate for the declining supply. In other words, a person will lose at least 50% of the dopamine in his or her brain before noticing that something is wrong with his or her body. We now also know that the non- motor features of PD arise from the loss of neurons in areas of the brain outside of the substantia nigra and involve chemicals other than dopamine, particularly acetylcholine. In 2011, a computerized brain scan utilizing a radio-isotope that labels the molecule transporting dopamine into the cell (DaTscan) first became available in the United States. A DaTscan may be used to assist with the clinical diagnosis of PD and other parkinsonian syndromes when the patient’s presenting symptoms are not straightforward. TREATMENT It is important for persons with PD to realize that although the underlying disease progresses slowly, the clinical course over many years varies greatly with each person. Effective management of PD symptoms requires an experienced and compassionate healthcare provider, the person with PD and his or her care partner to determine a treatment plan consisting of appropriate medications, regular exercise, a healthy diet, social engagement and cognitive activities, counseling and other therapies. As the disease progresses and problems accumulate, deep brain stimulation (DBS) surgery may be a reasonable therapeutic option for some individuals, although many people with PD do not qualify for DBS for a variety of reasons. However, the majority of people with PD can lead full and active lives with good symptom control for many years. 7 301277_NPF-Medications.indd 7 10/30/17 1:24 PM Parkinson’s Disease: Medications